Parnavel amlo Valium 5mg 4mg + 30 + pcs 1ozon

Description

Composition
Active substance:
1 tablet of 5 mg plus 4 mg: amlodipine besylate – 6.94 mg per amlodipine base – 5.0 mg iperindoprila erbumine – 4.0 mg 1 tablet of 10 mg + 8 mg: amlodipine besylate – 13.88 mg per -10.0 mg of amlodipine base and perindopril erbumine – 8.0 mg 1 tablet of 10 mg plus 4 mg: amlodipine besylate – 13.88 mg per amlodipine base – 10.0 mg of perindopril erbumine – 4.0 mg 1 tablet 5 mg + 8 mg: amlodipine besylate – 6.94 mg per amlodipine base – 5.0 mg of perindopril erbumine – 8.0 mg.
Product form:
Tablets of 5 mg plus 4 mg; 10 mg + 8 mg; 10 mg plus 4 mg and 5 mg + 8 mg. 10, 20, 30 tablets in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50 or 100 tablets per plastic jars for medicaments. One jar or 1, 2, 3, 4, 5, 6 or 10, the contour of cellular packaging together with instructions for use placed in a cardboard box (pack).
Contraindications
Perindopril – Hypersensitivity to perindopril or other ACE inhibitors; – Angioneurotic edema (Quincke’s edema) in the history (including patients receiving other ACE inhibitors); – Hereditary / idiopathic angioedema; – Age 18 years (effectiveness and safety have been established). – simultaneous use of perindopril and preparations containing aliskiren in patients with renal failure (creatinine clearance less than 60 mL / min) and patients with diabetes mellitus. Amlodipine – Hypersensitivity to amlodipine or other derivatives of dihydropyridine; – Severe hypotension (systolic blood pressure (BP) is less than 90 mm Hg..); – obstruction of the left ventricular outflow tract (e.g., expressed aortic stenosis); – Unstable angina (except Prinzmetal angina); – Age 18 years (effectiveness and safety have been established). – Shock (including cardiogenic). – haemodynamically unstable heart failure after acute myocardial infarction. Amlodipine Perindopril + – hypersensitivity to excipients entering into the composition of the formulation; – Renal failure (creatinine clearance (CC) of less than 60 ml / min); – Age 18 years (effectiveness and safety have been established); – Hereditary intolerance to lactose, lactase deficiency and glucose-galactose malabsorption.
Dosage
5 mg plus 4 mg
Indications
Hypertension and / or ischemic heart disease (IHD): stable angina in patients who require therapy with perindopril and amlodipine.
pharmachologic effect
Pharmacological group:
Hypotensive combined means (an inhibitor of angiotensin converting enzyme (ACE) + blocker “slow” calcium channel (BCCI)).
Pharmacological properties:
Perindopril – an inhibitor of angiotensin converting enzyme I to angiotensin II (ACE inhibitor). Angiotensin-converting enzyme, or kininaza II, is an exopeptidase, which carries out both the conversion of angiotensin I to the vasoconstrictor compound angiotensin II, and the destruction of bradykinin, which has vasodilatory action, to the inactive heptapeptide. Since ACE inactivates bradykinin, ACE inhibition accompanied by increased activity of both circulating and tissue kallikrein-kinin system, the system is also activated prostaglandins.
Perindopril has therapeutic effect due to the active metabolite, perindoprilat. Other metabolites do not have an inhibitory effect on ACE. Amlodipine – blocker “slow” calcium channel (BCCI), a dihydropyridine derivative. Amlodipine inhibits the transmembrane passage of ions of calcium into cardiomyocytes and smooth muscle cells of the vascular wall. The antihypertensive action of amlodipine is due to a direct effect on the smooth muscle cells of the vascular wall. It is found that amlodipine: • causes expansion of peripheral arterioles, reducing the total peripheral vascular resistance (afterload) since heart rate is not changed, and myocardial oxygen demand is reduced. • causes expansion of the coronary arteries and arterioles in ischemic and in intact areas. In patients with angina Prinzmetal while improving coronary blood flow. Amlodipine + Perindopril main criterion for evaluating the effectiveness of long-term use of amlodipine in combination with perindopril fixed-combination indicator nonfatal myocardial infarction (including, painless) and fatal coronary heart disease outcomes. The frequency of complications is reduced when used in combination with amlodipine perindopril.
Conditions of supply of pharmacies
Prescription.
Dosing and Administration
Inside, 1 tablet 1 time a day, preferably in the morning before eating. Dose Parnavel Amlo selected after a previous dose titration of the individual components of the preparation: perindopril and amlodipine in hypertensive patients and / or coronary heart disease. When the therapeutic necessity, the dose Parnavel Amlo may be changed or can previously be carried out individual selection of doses of the individual components: 4 mg perindopril + 5 mg amlodipine or 8 mg of perindopril + 5 mg amlodipine or 4 mg of perindopril + 10 mg of amlodipine or 8 mg of perindopril + 10 mg of amlodipine. Parnavel Amlo at doses of 4 mg perindopril + amlodipine and 10 mg 8 mg Perindopril + amlodipine is 10 mg maximum daily dose of the drug, which should not be exceeded.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist